Comparison of adverse events following immunization with pandemic influenza A (H1N1)pdm09 vaccine with or without adjuvant among health professionals in Rio de Janeiro, Brazil

Abstract

A vaccination campaign against pandemic influenza A (H1N1)pdm09 was held in Brazil in March 2010, using

Safety and immunogenicity of the novel seasonal preservative‐ and adjuvant‐free influenza vaccine: Blind, randomized, and placebo‐controlled trial

“…Therewith, for instance, one of authorized and widely used adjuvants, aluminium salts, mainly aluminium phosphate, or aluminium hydroxide may induce production of IgE that is responsible for allergenicity. 23 It has been proved that accumulation of this adjuvant in a body principally influences brain and bone tissues causing fatal neurological syndrome and dialysis-associated dementia. 24,25 Authors would like to show that the seasonal trivalent split vaccine manufactured without additives for stabilization and immunomodulation has lower reactogenicity than adjuvant vaccines and sufficient protective level of antibodies for its future use in vaccination of children and pregnant women.…”

“…SafetyWithin May[11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] 2016 in total 88 volunteers were screened for fitting inclusion/exclusion criteria of the trial. Anamneses of all screened persons were collected, physical examination of volunteers was carried out, their primary physiological characteristics were determined (height, weight, body temperature, blood pressure, pulse/ heart rate, and breathing rate), ECG data were obtained, venous blood for clinical, biochemical, and immunological assays was sampled, urine from all volunteers was analyzed, women were tested for pregnancy.…”

Efetividade da estratégia brasileira de vacinação contra influenza: uma revisão sistemática

“…Uma parte deles apresenta relatos de casos de eventos adversos raros [59][60][61][62][63][64][65][66] temporalmente associados à vacinação contra o subtipo pandêmico de 2009, tais como casos de Síndrome de Guillain-Barré, narcolepsia, paralisia oculomotora e rabdomiólise. Há também estudos transversais e de coorte, que incluíram os eventos adversos na investigação de razões para a não vacinação [67][68][69] e estudos em clientelas específicas, [70][71][72][73][74][75] além de estudos realizados entre profissionais de saúde 76 e indivíduos de 60 anos ou mais. 77,78 Discussão O propósito desta revisão foi buscar na literatura científica a resposta à pergunta se a estratégia brasileira de vacinação contra influenza vem logrando o seu objetivo de "reduzir a mortalidade, as complicações e as internações decorrentes das infecções pelo vírus da influenza, na população alvo".…”

Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults

“…accumulating in humans can be the health risk factor. [12][13][14] The RIBSP was a WHO grantee and received funding from the global action plan to increase the supply of influenza vaccine. This was an incredibly important initiative that aimed at the establishment of influenza vaccine production capacities in low-and middleincome countries, so that those countries were independent of vaccine supply from high-income countries (especially in case of a pandemic).…”